NBT Bank N A NY Sells 837 Shares of Danaher Corporation $DHR

NBT Bank N A NY lessened its holdings in shares of Danaher Corporation (NYSE:DHR) by 1.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,098 shares of the conglomerate’s stock after selling 837 shares during the quarter. NBT Bank N A NY’s holdings in Danaher were worth $8,514,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of DHR. Nuveen LLC bought a new position in shares of Danaher in the first quarter valued at approximately $833,941,000. Invesco Ltd. boosted its position in shares of Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the period. Baird Financial Group Inc. boosted its position in shares of Danaher by 290.6% in the first quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate’s stock valued at $295,550,000 after acquiring an additional 1,072,617 shares during the period. Generation Investment Management LLP boosted its position in shares of Danaher by 33.2% in the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate’s stock valued at $651,515,000 after acquiring an additional 791,662 shares during the period. Finally, Parnassus Investments LLC boosted its position in shares of Danaher by 23.3% in the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate’s stock valued at $784,745,000 after acquiring an additional 722,636 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Down 1.5%

DHR stock opened at $208.63 on Wednesday. The company has a market capitalization of $149.39 billion, a PE ratio of 44.39, a price-to-earnings-growth ratio of 3.02 and a beta of 0.77. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41. The company’s 50 day moving average price is $200.40 and its two-hundred day moving average price is $197.32. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business’s revenue was up 3.4% compared to the same quarter last year. During the same period last year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 27.23%.

Insider Activity at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 11.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DHR. Wells Fargo & Company cut their price objective on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 23rd. Robert W. Baird raised their price objective on shares of Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research report on Friday, July 18th. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Friday, June 27th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research note on Saturday, September 27th. Finally, Bank of America lowered their target price on shares of Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Seventeen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $246.74.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.